Interestingly, yesterday, Merck announced to acquire EyeBio for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments for a potential value of $3 billion.
Back in February 13, 2024 Eyebiotech had announced Week 12 data from its first-in-human Phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME, n=26) and with treatment-naïve neovascular age-related macular degeneration (NVAMD, n=5).
Patients with DME (n=26) received Restoret as monotherapy, manifesting a mean improvement in best-corrected visual acuity of +11.2 letters.
Similar outcomes were observed in patients with NVAMD (n=5), who received Restoret in combination with aflibercept (Eylea).
An improvement in BCVA of „similar to +11,2 letters“ in treatment naīve wAMD patients when given in combination with an anti-VEGF-A is nothing that OPT should feel particularly impressed with. Actually, all the opposite!
$3 BN = AUD 4.5 BN = AUD 6.75/share
For a drug that hasn‘t even started P2b.
Not bad. Not bad at all…
Hang in there!!, page-160
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $398.3M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 35.5¢ | $685.8K | 1.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 61550 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 48038 | 9 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |